Computational discovery of novel low micromolar human pregnane X receptor antagonists

Sean Ekins, Vladyslav Kholodovych, Ni Ai, Michael Sinz, Joseph Gal, Lajos Gera, William J. Welsh, Kenneth Bachmann, Sridhar Mani

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Very few antagonists have been identified for the human pregnane X receptor (PXR). These molecules may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this receptor (e.g., some anticancer compounds and macrolide antibiotics), with subsequent effects on transcriptional regulation of xenobiotic metabolism and transporter genes. A recent novel pharmacophore for PXR antagonists was developed using three azoles and consisted of two hydrogen bond acceptor regions and two hydrophobic features. This pharmacophore also suggested an overall small binding site that was identified on the outer surface of the receptor at the AF-2 site and validated by docking studies. Using computational approaches to search libraries of known drugs or commercially available molecules is preferred over random screening. We have now described several new smaller antagonists of PXR discovered with the antagonist pharmacophore with in vitro activity in the low micromolar range [S-p-tolyl 3′,5-dimethyl-3,5′-biisoxazole-4′-carbothioate (SPB03255) (IC50, 6.3 μM) and 4-(3-chlorophenyl)-5-(2,4-dichlorobenzylthio)- 4H-1,2,4-triazol-3-ol (SPB00574) (IC50, 24.8 μM)]. We have also used our computational pharmacophore and docking tools to suggest that most of the known PXR antagonists, such as coumestrol and sulforaphane, could also interact on the outer surface of PXR at the AF-2 domain. The involvement of this domain was also suggested by further site-directed mutagenesis work. We have additionally described an FDA approved prodrug, leflunomide (IC50, 6.8 μM), that seems to be a PXR antagonist in vitro. These observations are important for predicting whether further molecules may interact with PXR as antagonists in vivo with potential therapeutic applications.

Original languageEnglish (US)
Pages (from-to)662-672
Number of pages11
JournalMolecular Pharmacology
Volume74
Issue number3
DOIs
StatePublished - Sep 2008

Fingerprint

Furylfuramide
Inhibitory Concentration 50
leflunomide
Coumestrol
Azoles
Macrolides
Prodrugs
Therapeutic Uses
Xenobiotics
Site-Directed Mutagenesis
pregnane X receptor
Pharmaceutical Preparations
Libraries
Hydrogen
Binding Sites
Anti-Bacterial Agents
Genes
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Computational discovery of novel low micromolar human pregnane X receptor antagonists. / Ekins, Sean; Kholodovych, Vladyslav; Ai, Ni; Sinz, Michael; Gal, Joseph; Gera, Lajos; Welsh, William J.; Bachmann, Kenneth; Mani, Sridhar.

In: Molecular Pharmacology, Vol. 74, No. 3, 09.2008, p. 662-672.

Research output: Contribution to journalArticle

Ekins, S, Kholodovych, V, Ai, N, Sinz, M, Gal, J, Gera, L, Welsh, WJ, Bachmann, K & Mani, S 2008, 'Computational discovery of novel low micromolar human pregnane X receptor antagonists', Molecular Pharmacology, vol. 74, no. 3, pp. 662-672. https://doi.org/10.1124/mol.108.049437
Ekins, Sean ; Kholodovych, Vladyslav ; Ai, Ni ; Sinz, Michael ; Gal, Joseph ; Gera, Lajos ; Welsh, William J. ; Bachmann, Kenneth ; Mani, Sridhar. / Computational discovery of novel low micromolar human pregnane X receptor antagonists. In: Molecular Pharmacology. 2008 ; Vol. 74, No. 3. pp. 662-672.
@article{01d6026f617545c79869f2b178a18f43,
title = "Computational discovery of novel low micromolar human pregnane X receptor antagonists",
abstract = "Very few antagonists have been identified for the human pregnane X receptor (PXR). These molecules may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this receptor (e.g., some anticancer compounds and macrolide antibiotics), with subsequent effects on transcriptional regulation of xenobiotic metabolism and transporter genes. A recent novel pharmacophore for PXR antagonists was developed using three azoles and consisted of two hydrogen bond acceptor regions and two hydrophobic features. This pharmacophore also suggested an overall small binding site that was identified on the outer surface of the receptor at the AF-2 site and validated by docking studies. Using computational approaches to search libraries of known drugs or commercially available molecules is preferred over random screening. We have now described several new smaller antagonists of PXR discovered with the antagonist pharmacophore with in vitro activity in the low micromolar range [S-p-tolyl 3′,5-dimethyl-3,5′-biisoxazole-4′-carbothioate (SPB03255) (IC50, 6.3 μM) and 4-(3-chlorophenyl)-5-(2,4-dichlorobenzylthio)- 4H-1,2,4-triazol-3-ol (SPB00574) (IC50, 24.8 μM)]. We have also used our computational pharmacophore and docking tools to suggest that most of the known PXR antagonists, such as coumestrol and sulforaphane, could also interact on the outer surface of PXR at the AF-2 domain. The involvement of this domain was also suggested by further site-directed mutagenesis work. We have additionally described an FDA approved prodrug, leflunomide (IC50, 6.8 μM), that seems to be a PXR antagonist in vitro. These observations are important for predicting whether further molecules may interact with PXR as antagonists in vivo with potential therapeutic applications.",
author = "Sean Ekins and Vladyslav Kholodovych and Ni Ai and Michael Sinz and Joseph Gal and Lajos Gera and Welsh, {William J.} and Kenneth Bachmann and Sridhar Mani",
year = "2008",
month = "9",
doi = "10.1124/mol.108.049437",
language = "English (US)",
volume = "74",
pages = "662--672",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Computational discovery of novel low micromolar human pregnane X receptor antagonists

AU - Ekins, Sean

AU - Kholodovych, Vladyslav

AU - Ai, Ni

AU - Sinz, Michael

AU - Gal, Joseph

AU - Gera, Lajos

AU - Welsh, William J.

AU - Bachmann, Kenneth

AU - Mani, Sridhar

PY - 2008/9

Y1 - 2008/9

N2 - Very few antagonists have been identified for the human pregnane X receptor (PXR). These molecules may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this receptor (e.g., some anticancer compounds and macrolide antibiotics), with subsequent effects on transcriptional regulation of xenobiotic metabolism and transporter genes. A recent novel pharmacophore for PXR antagonists was developed using three azoles and consisted of two hydrogen bond acceptor regions and two hydrophobic features. This pharmacophore also suggested an overall small binding site that was identified on the outer surface of the receptor at the AF-2 site and validated by docking studies. Using computational approaches to search libraries of known drugs or commercially available molecules is preferred over random screening. We have now described several new smaller antagonists of PXR discovered with the antagonist pharmacophore with in vitro activity in the low micromolar range [S-p-tolyl 3′,5-dimethyl-3,5′-biisoxazole-4′-carbothioate (SPB03255) (IC50, 6.3 μM) and 4-(3-chlorophenyl)-5-(2,4-dichlorobenzylthio)- 4H-1,2,4-triazol-3-ol (SPB00574) (IC50, 24.8 μM)]. We have also used our computational pharmacophore and docking tools to suggest that most of the known PXR antagonists, such as coumestrol and sulforaphane, could also interact on the outer surface of PXR at the AF-2 domain. The involvement of this domain was also suggested by further site-directed mutagenesis work. We have additionally described an FDA approved prodrug, leflunomide (IC50, 6.8 μM), that seems to be a PXR antagonist in vitro. These observations are important for predicting whether further molecules may interact with PXR as antagonists in vivo with potential therapeutic applications.

AB - Very few antagonists have been identified for the human pregnane X receptor (PXR). These molecules may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this receptor (e.g., some anticancer compounds and macrolide antibiotics), with subsequent effects on transcriptional regulation of xenobiotic metabolism and transporter genes. A recent novel pharmacophore for PXR antagonists was developed using three azoles and consisted of two hydrogen bond acceptor regions and two hydrophobic features. This pharmacophore also suggested an overall small binding site that was identified on the outer surface of the receptor at the AF-2 site and validated by docking studies. Using computational approaches to search libraries of known drugs or commercially available molecules is preferred over random screening. We have now described several new smaller antagonists of PXR discovered with the antagonist pharmacophore with in vitro activity in the low micromolar range [S-p-tolyl 3′,5-dimethyl-3,5′-biisoxazole-4′-carbothioate (SPB03255) (IC50, 6.3 μM) and 4-(3-chlorophenyl)-5-(2,4-dichlorobenzylthio)- 4H-1,2,4-triazol-3-ol (SPB00574) (IC50, 24.8 μM)]. We have also used our computational pharmacophore and docking tools to suggest that most of the known PXR antagonists, such as coumestrol and sulforaphane, could also interact on the outer surface of PXR at the AF-2 domain. The involvement of this domain was also suggested by further site-directed mutagenesis work. We have additionally described an FDA approved prodrug, leflunomide (IC50, 6.8 μM), that seems to be a PXR antagonist in vitro. These observations are important for predicting whether further molecules may interact with PXR as antagonists in vivo with potential therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=50449109998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50449109998&partnerID=8YFLogxK

U2 - 10.1124/mol.108.049437

DO - 10.1124/mol.108.049437

M3 - Article

VL - 74

SP - 662

EP - 672

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 3

ER -